Johnson & Johnson (NYSE: JNJ) kicked off on Friday, up 0.26% from the previous trading day, before settling in for the closing price of $152.01. Over the past 52 weeks, JNJ has traded in a range of $140.68-$169.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 0.55%. While this was happening, its average annual earnings per share was recorded 6.33%. With a float of $2.40 billion, this company’s outstanding shares have now reached $2.41 billion.
Considering the fact that the conglomerate employs 138100 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 68.3%, operating margin of 24.71%, and the pretax margin is 29.78%.
Johnson & Johnson (JNJ) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Johnson & Johnson is 0.14%, while institutional ownership is 73.49%. The most recent insider transaction that took place on Feb 25 ’25, was worth 1,160,994. In this transaction VP Corporate Controller of this company sold 6,999 shares at a rate of $165.88, taking the stock ownership to the 21,001 shares. Before that another transaction happened on Feb 25 ’25, when Company’s Officer proposed sale 6,999 for $165.88, making the entire transaction worth $1,161,010.
Johnson & Johnson (JNJ) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 6.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.90% during the next five years compared to 0.55% growth over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Take a look at Johnson & Johnson’s (JNJ) current performance indicators. Last quarter, stock had a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.11. Likewise, its price to free cash flow for the trailing twelve months is 18.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.00, a number that is poised to hit 2.68 in the next quarter and is forecasted to reach 11.10 in one year’s time.
Technical Analysis of Johnson & Johnson (JNJ)
Compared to the last year’s volume of 9.18 million, its volume of 8.25 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 39.05%.
During the past 100 days, Johnson & Johnson’s (JNJ) raw stochastic average was set at 38.29%, which indicates a significant decrease from 39.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 13.25% in the past 14 days, which was lower than the 22.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $153.91, while its 200-day Moving Average is $155.73. Nevertheless, the first resistance level for the watch stands at $153.49 in the near term. At $154.57, the stock is likely to face the second major resistance level. The third major resistance level sits at $155.81. If the price goes on to break the first support level at $151.17, it is likely to go to the next support level at $149.93. Should the price break the second support level, the third support level stands at $148.85.
Johnson & Johnson (NYSE: JNJ) Key Stats
The company with the Market Capitalisation of 366.71 billion has total of 2,406,073K Shares Outstanding. Its annual sales at the moment are 88,821 M in contrast with the sum of 14,066 M annual income. Company’s last quarter sales were recorded 21,893 M and last quarter income was 10,999 M.
